Figure 5.

iNK-92 therapy of primary acute myeloid leukemia (AML) xenografted NOD/SCID gamma^null (NSG) mice. 3×10⁶ primary AML cells were injected intravenously (i.v.) via tail vein into irradiated NGS to establish disease in control (n=5) and therapy (n=5) mice. iNK-92 given intraperitoneally (i.p.) 20×20⁶ weekly for six weeks were used to treat AML xenografted mice starting ten days after inoculation (A). Mice were monitored for signs of leukemia and sacrificed at humane end points (B). Kaplan-Meier survival curves were generated to compare survival in control and treatment groups (P=0.0566).